Wolfgang Miesbach /LinkedIn
Sep 16, 2025, 02:44
Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“First reported inhibitor development in haemophilia A gene therapy Presented by Davide Matino at BIC meeting at Phase 3 giroctocogene fitelparvovec (AAV6, 3×10¹³ vg/kg, n=74).
Patient Profile:
- Genetic: Intron 22 inversion
- History: ITP + splenectomy
- Comorbidities: HCV & HIV co-infection
- Experience: 6,000 exposure days with FVIII
Clinical Timeline:
- Peak FVIII (day 75 after gene therapy): 441.7%
- Post-infusion: Multiple steroid courses for ↑ALT/AST
- Inhibitor development more than 1 year after treatment”
More recent insights on Hemostasis Today.
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals